In a 51-year-old male with major depressive disorder, insomnia, chronic respiratory failure with hypoxia, peripheral vascular disease, gastro‑esophageal reflux disease, restless legs syndrome, hyperlipidemia, hypotension related to hemodialysis, end‑stage renal disease, and type 2 diabetes mellitus, who has a history of huffing Lysol and other cleaners, what liquid or injectable medication can be ordered for acute inhalant (huffing) intoxication?

No Specific Medication for Inhalant Intoxication

There is no liquid or injectable medication specifically indicated for the treatment of inhalant (huffing) intoxication. Management of inhalant abuse and acute intoxication is entirely supportive, focusing on airway protection, oxygenation, hemodynamic stabilization, and treatment of complications as they arise.

Management Approach for Inhalant Intoxication

Acute Intoxication Management

The cornerstone of treatment for patients presenting with acute inhalant intoxication involves:

• Airway management: Establish and maintain a patent airway, provide supplemental oxygen
• Respiratory support: Bag-mask ventilation or endotracheal intubation if respiratory depression occurs
• Hemodynamic monitoring: Continuous cardiac monitoring for dysrhythmias (particularly ventricular arrhythmias from myocardial sensitization to catecholamines)
• Avoidance of catecholamines: Epinephrine and other sympathomimetics should be avoided when possible, as halogenated hydrocarbons (common in cleaning products) sensitize the myocardium and can precipitate fatal ventricular dysrhythmias

Specific Complications Requiring Treatment

For dysrhythmias:

• Beta-blockers (esmolol or propranolol) may be considered for tachyarrhythmias
• Lidocaine for ventricular dysrhythmias
• Avoid epinephrine and other direct sympathomimetics

For agitation or seizures:

• Benzodiazepines (lorazepam 2-4 mg IV or diazepam 5-10 mg IV) are first-line

For metabolic acidosis:

• Sodium bicarbonate may be indicated if severe (pH <7.1)

Critical Considerations in This Patient

This 51-year-old patient presents multiple high-risk factors that complicate management:

• End-stage renal disease on hemodialysis: Severely limits medication clearance; most sedatives and supportive medications require dose adjustment or are contraindicated
• Chronic respiratory failure with hypoxia: Baseline compromised respiratory status increases risk of respiratory arrest with CNS depressants
• Multiple CNS-active medications: Already on bupropion (lowers seizure threshold), ropinirole, and melatonin
• Cardiovascular disease: Peripheral vascular disease and use of clopidogrel increase bleeding risk; midodrine for hypotension complicates hemodynamic management

Long-Term Management Strategy

For substance use disorder treatment:

• Psychiatric consultation for underlying depression and substance use disorder
• Consider adjusting bupropion dose or switching antidepressants (bupropion may be less effective in ESRD and increases seizure risk)
• Behavioral interventions and addiction counseling are the primary evidence-based treatments for inhalant use disorder
• No FDA-approved pharmacotherapy exists for inhalant use disorder

Monitoring considerations:

• Screen for cognitive impairment and neurological sequelae from chronic inhalant exposure
• Assess for hepatotoxicity and bone marrow suppression (common with chronic solvent exposure)
• Evaluate cardiac function given risk of cardiomyopathy from chronic inhalant abuse

Common Pitfalls

1. Do not administer epinephrine or other direct sympathomimetics in acute inhalant intoxication due to risk of fatal dysrhythmias
2. Avoid aggressive fluid resuscitation in this patient with ESRD and chronic pulmonary edema
3. Do not use flumazenil if benzodiazepines are needed for agitation—this patient is on bupropion which lowers seizure threshold 1
4. Recognize that standard toxicology screens do not detect inhalants—diagnosis is clinical

The 2023 AHA guidelines on poisoning management 1 emphasize that consultation with a regional poison center (1-800-222-1222) or medical toxicologist is strongly recommended for complex cases like this, where multiple comorbidities and polypharmacy complicate supportive care decisions.